Biogen (BIIB) is trading lower today as selling pressure followed an analyst downgrade that questioned the company’s growth outlook and emphasized the high-risk nature of its late-stage pipeline. The downgrade reduced risk appetite into a catalyst-heavy stretch, pushing shares down roughly in line with the reported move.

The stock’s drop is landing just ahead of an FDA action date of April 3, 2026 for Biogen’s high-dose SPINRAZA (nusinersen) supplemental filing, a decision that investors view as an important lever for defending and potentially re-accelerating the spinal muscular atrophy franchise. With a binary regulatory event close on the calendar, positioning can turn more cautious, making the stock more sensitive to negative rating changes and broader market risk-off flows.

Near-term attention stays on the April 3 FDA decision and any updates to launch expectations and payer dynamics if the regimen is cleared. Beyond that, investors are balancing ongoing erosion in legacy multiple sclerosis revenue against pipeline readouts and regulatory milestones expected through 2026, which will shape whether Biogen can sustain a durable growth narrative.